Summary

The global Tumor Biomarker Testing market size is predicted to grow from US$ 11837 million in 2025 to US$ 24467 million in 2032; it is expected to grow at a CAGR of 11.1% from 2026 to 2032.
Tumor Biomarker Testing refers to the broad category of diagnostic products and testing services used to analyze measurable features associated with malignant tumors for diagnosis, classification, therapy selection, treatment monitoring, recurrence surveillance, and prognosis assessment. The analytes covered by Tumor Biomarker Testing may include protein markers, DNA mutations, RNA fusions, copy number variations, methylation signatures, microsatellite instability, tumor mutational burden, PD-L1 expression, circulating tumor DNA, and circulating tumor cells in tissue, blood, bone marrow, cells, or other body fluid samples. In commercial form, Tumor Biomarker Testing may appear as central-laboratory testing services, PCR kits, NGS panels, IHC/ISH reagents, cartridge-based automated systems, quality controls, and integrated software-reporting solutions. Its structure usually includes sample collection and preservation media, pre-analytical reagents, amplification or hybridization chemistry, signal detection instruments, bioinformatics interpretation modules, and clinical reporting. The core principle is to convert reproducible molecular or cellular abnormalities of cancer into clinically actionable information.
The growth of Tumor Biomarker Testing is fundamentally supported by the rising global cancer burden and the deeper penetration of precision oncology. With around 20 million new cancer cases worldwide in 2022 and a continued shift toward targeted therapy, immunotherapy, and biomarker-guided treatment, clinical practice is moving from single-gene testing toward comprehensive biomarker testing and comprehensive genomic profiling. Guideline adoption and expanding drug-label linkage are driving demand for tissue testing, liquid biopsy, companion diagnostics, and MRD monitoring.
The major restraints remain access, reimbursement, standardization, and real-world implementation efficiency. Many patients still do not receive complete biomarker testing early enough in the treatment pathway, while tissue inadequacy, workflow fragmentation, inter-laboratory variability, low-shedding ctDNA, result interpretation complexity, and uneven payment coverage continue to limit adoption. For suppliers, regulatory compliance, evidence generation, quality systems, and secure data handling raise barriers to scale.
Downstream demand is shifting from one-time testing toward longitudinal, multi-sample, and multi-technology testing. Hospitals increasingly prefer integrated solutions that cover DNA, RNA, protein, and immune-related markers with faster turnaround and less tissue consumption. Advanced solid tumor care is moving toward broader pan-cancer panels and liquid biopsy, while post-surgical and treatment-monitoring settings are accelerating demand for ctDNA-MRD and recurrence surveillance. As a result, decentralized cartridge systems and centralized high-complexity genomic labs will continue to coexist, serving different clinical needs.
LPI (LP Information)' newest research report, the “Tumor Biomarker Testing Industry Forecast” looks at past sales and reviews total world Tumor Biomarker Testing sales in 2025, providing a comprehensive analysis by region and market sector of projected Tumor Biomarker Testing sales for 2026 through 2032. With Tumor Biomarker Testing sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Tumor Biomarker Testing industry.
This Insight Report provides a comprehensive analysis of the global Tumor Biomarker Testing landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Tumor Biomarker Testing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Tumor Biomarker Testing market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Tumor Biomarker Testing and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Tumor Biomarker Testing.
This report presents a comprehensive overview, market shares, and growth opportunities of Tumor Biomarker Testing market by product type, application, key players and key regions and countries.
Segmentation by Type:
DNA Biomarker Testing
RNA Biomarker Testing
Protein Biomarker Testing
Cell-based Biomarker Testing
Multi-analyte Biomarker Testing
Segmentation by Sample Source:
Tissue-based Testing
Blood-based Testing
Bone Marrow-based Testing
Other Body Fluid-based Testing
Segmentation by Delivery Model:
Central Laboratory Testing
Hospital In-house Testing
Segmentation by Detection Technology:
Sequencing-based Testing
PCR-based Testing
Immunoassay-based Testing
Hybridization-based Testing
Cell Analysis-based Testing
Segmentation by Application:
Lung Cancer
Breast Cancer
Colorectal
Prostate Cancer
Blood Cancer
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Abbott Laboratories
Agilent Technologies
Roche
Thermo Fisher Scientific
QIAGEN
Illumina
DiaSorin
Fujirebio
Siemens Healthineers
Quest Diagnostics
Labcorp
NeoGenomics
Exact Sciences
Myriad Genetics
Guardant Health
Caris Life Sciences
Tempus AI
Natera
Personalis
Invivoscribe
Biocartis
Sysmex
Leica Biosystems
Cepheid
Menarini Silicon Biosystems
Veracyte
Castle Biosciences
OncoDNA
ACT Genomics
GC Genome
Burning Rock
Amoy Diagnostics
Genetron Health
3DMed Diagnostics
Singlera Genomics
BGI Genomics
Geneseeq
Genecast

ページTOPに戻る

Table of Contents

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Tumor Biomarker Testing Market Size (2021-2032)
2.1.2 Tumor Biomarker Testing Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Tumor Biomarker Testing by Country/Region (2021, 2025 & 2032)
2.2 Tumor Biomarker Testing Segment by Type
2.2.1 DNA Biomarker Testing
2.2.2 RNA Biomarker Testing
2.2.3 Protein Biomarker Testing
2.2.4 Cell-based Biomarker Testing
2.2.5 Multi-analyte Biomarker Testing
2.2.6 Tumor Biomarker Testing Market Size by Type
2.2.6.1 Tumor Biomarker Testing Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.6.2 Global Tumor Biomarker Testing Market Size Market Share by Type (2021-2026)
2.3 Tumor Biomarker Testing Segment by Sample Source
2.3.1 Tissue-based Testing
2.3.2 Blood-based Testing
2.3.3 Bone Marrow-based Testing
2.3.4 Other Body Fluid-based Testing
2.3.5 Tumor Biomarker Testing Market Size by Sample Source
2.3.5.1 Tumor Biomarker Testing Market Size CAGR by Sample Source (2021 VS 2025 VS 2032)
2.3.5.2 Global Tumor Biomarker Testing Market Size Market Share by Sample Source (2021-2026)
2.4 Tumor Biomarker Testing Segment by Delivery Model
2.4.1 Central Laboratory Testing
2.4.2 Hospital In-house Testing
2.4.3 Tumor Biomarker Testing Market Size by Delivery Model
2.4.3.1 Tumor Biomarker Testing Market Size CAGR by Delivery Model (2021 VS 2025 VS 2032)
2.4.3.2 Global Tumor Biomarker Testing Market Size Market Share by Delivery Model (2021-2026)
2.5 Tumor Biomarker Testing Segment by Detection Technology
2.5.1 Sequencing-based Testing
2.5.2 PCR-based Testing
2.5.3 Immunoassay-based Testing
2.5.4 Hybridization-based Testing
2.5.5 Cell Analysis-based Testing
2.5.6 Tumor Biomarker Testing Market Size by Detection Technology
2.5.6.1 Tumor Biomarker Testing Market Size CAGR by Detection Technology (2021 VS 2025 VS 2032)
2.5.6.2 Global Tumor Biomarker Testing Market Size Market Share by Detection Technology (2021-2026)
2.6 Tumor Biomarker Testing Segment by Application
2.6.1 Lung Cancer
2.6.2 Breast Cancer
2.6.3 Colorectal
2.6.4 Prostate Cancer
2.6.5 Blood Cancer
2.6.6 Tumor Biomarker Testing Market Size by Application
2.6.6.1 Tumor Biomarker Testing Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.6.6.2 Global Tumor Biomarker Testing Market Size Market Share by Application (2021-2026)
3 Tumor Biomarker Testing Market Size by Player
3.1 Tumor Biomarker Testing Market Size Market Share by Player
3.1.1 Global Tumor Biomarker Testing Revenue by Player (2021-2026)
3.1.2 Global Tumor Biomarker Testing Revenue Market Share by Player (2021-2026)
3.2 Global Tumor Biomarker Testing Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Tumor Biomarker Testing by Region
4.1 Tumor Biomarker Testing Market Size by Region (2021-2026)
4.2 Global Tumor Biomarker Testing Annual Revenue by Country/Region (2021-2026)
4.3 Americas Tumor Biomarker Testing Market Size Growth (2021-2026)
4.4 APAC Tumor Biomarker Testing Market Size Growth (2021-2026)
4.5 Europe Tumor Biomarker Testing Market Size Growth (2021-2026)
4.6 Middle East & Africa Tumor Biomarker Testing Market Size Growth (2021-2026)
5 Americas
5.1 Americas Tumor Biomarker Testing Market Size by Country (2021-2026)
5.2 Americas Tumor Biomarker Testing Market Size by Type (2021-2026)
5.3 Americas Tumor Biomarker Testing Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Tumor Biomarker Testing Market Size by Region (2021-2026)
6.2 APAC Tumor Biomarker Testing Market Size by Type (2021-2026)
6.3 APAC Tumor Biomarker Testing Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Tumor Biomarker Testing Market Size by Country (2021-2026)
7.2 Europe Tumor Biomarker Testing Market Size by Type (2021-2026)
7.3 Europe Tumor Biomarker Testing Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Tumor Biomarker Testing by Region (2021-2026)
8.2 Middle East & Africa Tumor Biomarker Testing Market Size by Type (2021-2026)
8.3 Middle East & Africa Tumor Biomarker Testing Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Tumor Biomarker Testing Market Forecast
10.1 Global Tumor Biomarker Testing Forecast by Region (2027-2032)
10.1.1 Global Tumor Biomarker Testing Forecast by Region (2027-2032)
10.1.2 Americas Tumor Biomarker Testing Forecast
10.1.3 APAC Tumor Biomarker Testing Forecast
10.1.4 Europe Tumor Biomarker Testing Forecast
10.1.5 Middle East & Africa Tumor Biomarker Testing Forecast
10.2 Americas Tumor Biomarker Testing Forecast by Country (2027-2032)
10.2.1 United States Market Tumor Biomarker Testing Forecast
10.2.2 Canada Market Tumor Biomarker Testing Forecast
10.2.3 Mexico Market Tumor Biomarker Testing Forecast
10.2.4 Brazil Market Tumor Biomarker Testing Forecast
10.3 APAC Tumor Biomarker Testing Forecast by Region (2027-2032)
10.3.1 China Tumor Biomarker Testing Market Forecast
10.3.2 Japan Market Tumor Biomarker Testing Forecast
10.3.3 Korea Market Tumor Biomarker Testing Forecast
10.3.4 Southeast Asia Market Tumor Biomarker Testing Forecast
10.3.5 India Market Tumor Biomarker Testing Forecast
10.3.6 Australia Market Tumor Biomarker Testing Forecast
10.4 Europe Tumor Biomarker Testing Forecast by Country (2027-2032)
10.4.1 Germany Market Tumor Biomarker Testing Forecast
10.4.2 France Market Tumor Biomarker Testing Forecast
10.4.3 UK Market Tumor Biomarker Testing Forecast
10.4.4 Italy Market Tumor Biomarker Testing Forecast
10.4.5 Russia Market Tumor Biomarker Testing Forecast
10.5 Middle East & Africa Tumor Biomarker Testing Forecast by Region (2027-2032)
10.5.1 Egypt Market Tumor Biomarker Testing Forecast
10.5.2 South Africa Market Tumor Biomarker Testing Forecast
10.5.3 Israel Market Tumor Biomarker Testing Forecast
10.5.4 Turkey Market Tumor Biomarker Testing Forecast
10.6 Global Tumor Biomarker Testing Forecast by Type (2027-2032)
10.7 Global Tumor Biomarker Testing Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Tumor Biomarker Testing Forecast
11 Key Players Analysis
11.1 Abbott Laboratories
11.1.1 Abbott Laboratories Company Information
11.1.2 Abbott Laboratories Tumor Biomarker Testing Product Offered
11.1.3 Abbott Laboratories Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Abbott Laboratories Main Business Overview
11.1.5 Abbott Laboratories Latest Developments
11.2 Agilent Technologies
11.2.1 Agilent Technologies Company Information
11.2.2 Agilent Technologies Tumor Biomarker Testing Product Offered
11.2.3 Agilent Technologies Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Agilent Technologies Main Business Overview
11.2.5 Agilent Technologies Latest Developments
11.3 Roche
11.3.1 Roche Company Information
11.3.2 Roche Tumor Biomarker Testing Product Offered
11.3.3 Roche Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Roche Main Business Overview
11.3.5 Roche Latest Developments
11.4 Thermo Fisher Scientific
11.4.1 Thermo Fisher Scientific Company Information
11.4.2 Thermo Fisher Scientific Tumor Biomarker Testing Product Offered
11.4.3 Thermo Fisher Scientific Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Thermo Fisher Scientific Main Business Overview
11.4.5 Thermo Fisher Scientific Latest Developments
11.5 QIAGEN
11.5.1 QIAGEN Company Information
11.5.2 QIAGEN Tumor Biomarker Testing Product Offered
11.5.3 QIAGEN Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 QIAGEN Main Business Overview
11.5.5 QIAGEN Latest Developments
11.6 Illumina
11.6.1 Illumina Company Information
11.6.2 Illumina Tumor Biomarker Testing Product Offered
11.6.3 Illumina Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Illumina Main Business Overview
11.6.5 Illumina Latest Developments
11.7 DiaSorin
11.7.1 DiaSorin Company Information
11.7.2 DiaSorin Tumor Biomarker Testing Product Offered
11.7.3 DiaSorin Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 DiaSorin Main Business Overview
11.7.5 DiaSorin Latest Developments
11.8 Fujirebio
11.8.1 Fujirebio Company Information
11.8.2 Fujirebio Tumor Biomarker Testing Product Offered
11.8.3 Fujirebio Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Fujirebio Main Business Overview
11.8.5 Fujirebio Latest Developments
11.9 Siemens Healthineers
11.9.1 Siemens Healthineers Company Information
11.9.2 Siemens Healthineers Tumor Biomarker Testing Product Offered
11.9.3 Siemens Healthineers Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Siemens Healthineers Main Business Overview
11.9.5 Siemens Healthineers Latest Developments
11.10 Quest Diagnostics
11.10.1 Quest Diagnostics Company Information
11.10.2 Quest Diagnostics Tumor Biomarker Testing Product Offered
11.10.3 Quest Diagnostics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Quest Diagnostics Main Business Overview
11.10.5 Quest Diagnostics Latest Developments
11.11 Labcorp
11.11.1 Labcorp Company Information
11.11.2 Labcorp Tumor Biomarker Testing Product Offered
11.11.3 Labcorp Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Labcorp Main Business Overview
11.11.5 Labcorp Latest Developments
11.12 NeoGenomics
11.12.1 NeoGenomics Company Information
11.12.2 NeoGenomics Tumor Biomarker Testing Product Offered
11.12.3 NeoGenomics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 NeoGenomics Main Business Overview
11.12.5 NeoGenomics Latest Developments
11.13 Exact Sciences
11.13.1 Exact Sciences Company Information
11.13.2 Exact Sciences Tumor Biomarker Testing Product Offered
11.13.3 Exact Sciences Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 Exact Sciences Main Business Overview
11.13.5 Exact Sciences Latest Developments
11.14 Myriad Genetics
11.14.1 Myriad Genetics Company Information
11.14.2 Myriad Genetics Tumor Biomarker Testing Product Offered
11.14.3 Myriad Genetics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 Myriad Genetics Main Business Overview
11.14.5 Myriad Genetics Latest Developments
11.15 Guardant Health
11.15.1 Guardant Health Company Information
11.15.2 Guardant Health Tumor Biomarker Testing Product Offered
11.15.3 Guardant Health Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 Guardant Health Main Business Overview
11.15.5 Guardant Health Latest Developments
11.16 Caris Life Sciences
11.16.1 Caris Life Sciences Company Information
11.16.2 Caris Life Sciences Tumor Biomarker Testing Product Offered
11.16.3 Caris Life Sciences Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 Caris Life Sciences Main Business Overview
11.16.5 Caris Life Sciences Latest Developments
11.17 Tempus AI
11.17.1 Tempus AI Company Information
11.17.2 Tempus AI Tumor Biomarker Testing Product Offered
11.17.3 Tempus AI Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
11.17.4 Tempus AI Main Business Overview
11.17.5 Tempus AI Latest Developments
11.18 Natera
11.18.1 Natera Company Information
11.18.2 Natera Tumor Biomarker Testing Product Offered
11.18.3 Natera Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
11.18.4 Natera Main Business Overview
11.18.5 Natera Latest Developments
11.19 Personalis
11.19.1 Personalis Company Information
11.19.2 Personalis Tumor Biomarker Testing Product Offered
11.19.3 Personalis Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
11.19.4 Personalis Main Business Overview
11.19.5 Personalis Latest Developments
11.20 Invivoscribe
11.20.1 Invivoscribe Company Information
11.20.2 Invivoscribe Tumor Biomarker Testing Product Offered
11.20.3 Invivoscribe Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
11.20.4 Invivoscribe Main Business Overview
11.20.5 Invivoscribe Latest Developments
11.21 Biocartis
11.21.1 Biocartis Company Information
11.21.2 Biocartis Tumor Biomarker Testing Product Offered
11.21.3 Biocartis Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
11.21.4 Biocartis Main Business Overview
11.21.5 Biocartis Latest Developments
11.22 Sysmex
11.22.1 Sysmex Company Information
11.22.2 Sysmex Tumor Biomarker Testing Product Offered
11.22.3 Sysmex Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
11.22.4 Sysmex Main Business Overview
11.22.5 Sysmex Latest Developments
11.23 Leica Biosystems
11.23.1 Leica Biosystems Company Information
11.23.2 Leica Biosystems Tumor Biomarker Testing Product Offered
11.23.3 Leica Biosystems Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
11.23.4 Leica Biosystems Main Business Overview
11.23.5 Leica Biosystems Latest Developments
11.24 Cepheid
11.24.1 Cepheid Company Information
11.24.2 Cepheid Tumor Biomarker Testing Product Offered
11.24.3 Cepheid Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
11.24.4 Cepheid Main Business Overview
11.24.5 Cepheid Latest Developments
11.25 Menarini Silicon Biosystems
11.25.1 Menarini Silicon Biosystems Company Information
11.25.2 Menarini Silicon Biosystems Tumor Biomarker Testing Product Offered
11.25.3 Menarini Silicon Biosystems Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
11.25.4 Menarini Silicon Biosystems Main Business Overview
11.25.5 Menarini Silicon Biosystems Latest Developments
11.26 Veracyte
11.26.1 Veracyte Company Information
11.26.2 Veracyte Tumor Biomarker Testing Product Offered
11.26.3 Veracyte Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
11.26.4 Veracyte Main Business Overview
11.26.5 Veracyte Latest Developments
11.27 Castle Biosciences
11.27.1 Castle Biosciences Company Information
11.27.2 Castle Biosciences Tumor Biomarker Testing Product Offered
11.27.3 Castle Biosciences Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
11.27.4 Castle Biosciences Main Business Overview
11.27.5 Castle Biosciences Latest Developments
11.28 OncoDNA
11.28.1 OncoDNA Company Information
11.28.2 OncoDNA Tumor Biomarker Testing Product Offered
11.28.3 OncoDNA Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
11.28.4 OncoDNA Main Business Overview
11.28.5 OncoDNA Latest Developments
11.29 ACT Genomics
11.29.1 ACT Genomics Company Information
11.29.2 ACT Genomics Tumor Biomarker Testing Product Offered
11.29.3 ACT Genomics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
11.29.4 ACT Genomics Main Business Overview
11.29.5 ACT Genomics Latest Developments
11.30 GC Genome
11.30.1 GC Genome Company Information
11.30.2 GC Genome Tumor Biomarker Testing Product Offered
11.30.3 GC Genome Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
11.30.4 GC Genome Main Business Overview
11.30.5 GC Genome Latest Developments
11.31 Burning Rock
11.31.1 Burning Rock Company Information
11.31.2 Burning Rock Tumor Biomarker Testing Product Offered
11.31.3 Burning Rock Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
11.31.4 Burning Rock Main Business Overview
11.31.5 Burning Rock Latest Developments
11.32 Amoy Diagnostics
11.32.1 Amoy Diagnostics Company Information
11.32.2 Amoy Diagnostics Tumor Biomarker Testing Product Offered
11.32.3 Amoy Diagnostics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
11.32.4 Amoy Diagnostics Main Business Overview
11.32.5 Amoy Diagnostics Latest Developments
11.33 Genetron Health
11.33.1 Genetron Health Company Information
11.33.2 Genetron Health Tumor Biomarker Testing Product Offered
11.33.3 Genetron Health Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
11.33.4 Genetron Health Main Business Overview
11.33.5 Genetron Health Latest Developments
11.34 3DMed Diagnostics
11.34.1 3DMed Diagnostics Company Information
11.34.2 3DMed Diagnostics Tumor Biomarker Testing Product Offered
11.34.3 3DMed Diagnostics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
11.34.4 3DMed Diagnostics Main Business Overview
11.34.5 3DMed Diagnostics Latest Developments
11.35 Singlera Genomics
11.35.1 Singlera Genomics Company Information
11.35.2 Singlera Genomics Tumor Biomarker Testing Product Offered
11.35.3 Singlera Genomics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
11.35.4 Singlera Genomics Main Business Overview
11.35.5 Singlera Genomics Latest Developments
11.36 BGI Genomics
11.36.1 BGI Genomics Company Information
11.36.2 BGI Genomics Tumor Biomarker Testing Product Offered
11.36.3 BGI Genomics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
11.36.4 BGI Genomics Main Business Overview
11.36.5 BGI Genomics Latest Developments
11.37 Geneseeq
11.37.1 Geneseeq Company Information
11.37.2 Geneseeq Tumor Biomarker Testing Product Offered
11.37.3 Geneseeq Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
11.37.4 Geneseeq Main Business Overview
11.37.5 Geneseeq Latest Developments
11.38 Genecast
11.38.1 Genecast Company Information
11.38.2 Genecast Tumor Biomarker Testing Product Offered
11.38.3 Genecast Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
11.38.4 Genecast Main Business Overview
11.38.5 Genecast Latest Developments
12 Research Findings and Conclusion

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Tumor Biomarker Testing Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Tumor Biomarker Testing Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of DNA Biomarker Testing
Table 4. Major Players of RNA Biomarker Testing
Table 5. Major Players of Protein Biomarker Testing
Table 6. Major Players of Cell-based Biomarker Testing
Table 7. Major Players of Multi-analyte Biomarker Testing
Table 8. Tumor Biomarker Testing Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 9. Global Tumor Biomarker Testing Market Size by Type (2021-2026) & ($ millions)
Table 10. Global Tumor Biomarker Testing Market Size Market Share by Type (2021-2026)
Table 11. Major Players of Tissue-based Testing
Table 12. Major Players of Blood-based Testing
Table 13. Major Players of Bone Marrow-based Testing
Table 14. Major Players of Other Body Fluid-based Testing
Table 15. Tumor Biomarker Testing Market Size CAGR by Sample Source (2021 VS 2025 VS 2032) & ($ millions)
Table 16. Global Tumor Biomarker Testing Market Size by Sample Source (2021-2026) & ($ millions)
Table 17. Global Tumor Biomarker Testing Market Size Market Share by Sample Source (2021-2026)
Table 18. Major Players of Central Laboratory Testing
Table 19. Major Players of Hospital In-house Testing
Table 20. Tumor Biomarker Testing Market Size CAGR by Delivery Model (2021 VS 2025 VS 2032) & ($ millions)
Table 21. Global Tumor Biomarker Testing Market Size by Delivery Model (2021-2026) & ($ millions)
Table 22. Global Tumor Biomarker Testing Market Size Market Share by Delivery Model (2021-2026)
Table 23. Major Players of Sequencing-based Testing
Table 24. Major Players of PCR-based Testing
Table 25. Major Players of Immunoassay-based Testing
Table 26. Major Players of Hybridization-based Testing
Table 27. Major Players of Cell Analysis-based Testing
Table 28. Tumor Biomarker Testing Market Size CAGR by Detection Technology (2021 VS 2025 VS 2032) & ($ millions)
Table 29. Global Tumor Biomarker Testing Market Size by Detection Technology (2021-2026) & ($ millions)
Table 30. Global Tumor Biomarker Testing Market Size Market Share by Detection Technology (2021-2026)
Table 31. Tumor Biomarker Testing Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 32. Global Tumor Biomarker Testing Market Size by Application (2021-2026) & ($ millions)
Table 33. Global Tumor Biomarker Testing Market Size Market Share by Application (2021-2026)
Table 34. Global Tumor Biomarker Testing Revenue by Player (2021-2026) & ($ millions)
Table 35. Global Tumor Biomarker Testing Revenue Market Share by Player (2021-2026)
Table 36. Tumor Biomarker Testing Key Players Head office and Products Offered
Table 37. Tumor Biomarker Testing Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 38. New Products and Potential Entrants
Table 39. Mergers & Acquisitions, Expansion
Table 40. Global Tumor Biomarker Testing Market Size by Region (2021-2026) & ($ millions)
Table 41. Global Tumor Biomarker Testing Market Size Market Share by Region (2021-2026)
Table 42. Global Tumor Biomarker Testing Revenue by Country/Region (2021-2026) & ($ millions)
Table 43. Global Tumor Biomarker Testing Revenue Market Share by Country/Region (2021-2026)
Table 44. Americas Tumor Biomarker Testing Market Size by Country (2021-2026) & ($ millions)
Table 45. Americas Tumor Biomarker Testing Market Size Market Share by Country (2021-2026)
Table 46. Americas Tumor Biomarker Testing Market Size by Type (2021-2026) & ($ millions)
Table 47. Americas Tumor Biomarker Testing Market Size Market Share by Type (2021-2026)
Table 48. Americas Tumor Biomarker Testing Market Size by Application (2021-2026) & ($ millions)
Table 49. Americas Tumor Biomarker Testing Market Size Market Share by Application (2021-2026)
Table 50. APAC Tumor Biomarker Testing Market Size by Region (2021-2026) & ($ millions)
Table 51. APAC Tumor Biomarker Testing Market Size Market Share by Region (2021-2026)
Table 52. APAC Tumor Biomarker Testing Market Size by Type (2021-2026) & ($ millions)
Table 53. APAC Tumor Biomarker Testing Market Size by Application (2021-2026) & ($ millions)
Table 54. Europe Tumor Biomarker Testing Market Size by Country (2021-2026) & ($ millions)
Table 55. Europe Tumor Biomarker Testing Market Size Market Share by Country (2021-2026)
Table 56. Europe Tumor Biomarker Testing Market Size by Type (2021-2026) & ($ millions)
Table 57. Europe Tumor Biomarker Testing Market Size by Application (2021-2026) & ($ millions)
Table 58. Middle East & Africa Tumor Biomarker Testing Market Size by Region (2021-2026) & ($ millions)
Table 59. Middle East & Africa Tumor Biomarker Testing Market Size by Type (2021-2026) & ($ millions)
Table 60. Middle East & Africa Tumor Biomarker Testing Market Size by Application (2021-2026) & ($ millions)
Table 61. Key Market Drivers & Growth Opportunities of Tumor Biomarker Testing
Table 62. Key Market Challenges & Risks of Tumor Biomarker Testing
Table 63. Key Industry Trends of Tumor Biomarker Testing
Table 64. Global Tumor Biomarker Testing Market Size Forecast by Region (2027-2032) & ($ millions)
Table 65. Global Tumor Biomarker Testing Market Size Market Share Forecast by Region (2027-2032)
Table 66. Global Tumor Biomarker Testing Market Size Forecast by Type (2027-2032) & ($ millions)
Table 67. Global Tumor Biomarker Testing Market Size Forecast by Application (2027-2032) & ($ millions)
Table 68. Abbott Laboratories Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors
Table 69. Abbott Laboratories Tumor Biomarker Testing Product Offered
Table 70. Abbott Laboratories Tumor Biomarker Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 71. Abbott Laboratories Main Business
Table 72. Abbott Laboratories Latest Developments
Table 73. Agilent Technologies Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors
Table 74. Agilent Technologies Tumor Biomarker Testing Product Offered
Table 75. Agilent Technologies Tumor Biomarker Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 76. Agilent Technologies Main Business
Table 77. Agilent Technologies Latest Developments
Table 78. Roche Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors
Table 79. Roche Tumor Biomarker Testing Product Offered
Table 80. Roche Tumor Biomarker Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 81. Roche Main Business
Table 82. Roche Latest Developments
Table 83. Thermo Fisher Scientific Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors
Table 84. Thermo Fisher Scientific Tumor Biomarker Testing Product Offered
Table 85. Thermo Fisher Scientific Tumor Biomarker Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 86. Thermo Fisher Scientific Main Business
Table 87. Thermo Fisher Scientific Latest Developments
Table 88. QIAGEN Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors
Table 89. QIAGEN Tumor Biomarker Testing Product Offered
Table 90. QIAGEN Tumor Biomarker Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 91. QIAGEN Main Business
Table 92. QIAGEN Latest Developments
Table 93. Illumina Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors
Table 94. Illumina Tumor Biomarker Testing Product Offered
Table 95. Illumina Tumor Biomarker Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 96. Illumina Main Business
Table 97. Illumina Latest Developments
Table 98. DiaSorin Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors
Table 99. DiaSorin Tumor Biomarker Testing Product Offered
Table 100. DiaSorin Tumor Biomarker Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 101. DiaSorin Main Business
Table 102. DiaSorin Latest Developments
Table 103. Fujirebio Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors
Table 104. Fujirebio Tumor Biomarker Testing Product Offered
Table 105. Fujirebio Tumor Biomarker Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 106. Fujirebio Main Business
Table 107. Fujirebio Latest Developments
Table 108. Siemens Healthineers Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors
Table 109. Siemens Healthineers Tumor Biomarker Testing Product Offered
Table 110. Siemens Healthineers Tumor Biomarker Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 111. Siemens Healthineers Main Business
Table 112. Siemens Healthineers Latest Developments
Table 113. Quest Diagnostics Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors
Table 114. Quest Diagnostics Tumor Biomarker Testing Product Offered
Table 115. Quest Diagnostics Tumor Biomarker Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 116. Quest Diagnostics Main Business
Table 117. Quest Diagnostics Latest Developments
Table 118. Labcorp Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors
Table 119. Labcorp Tumor Biomarker Testing Product Offered
Table 120. Labcorp Tumor Biomarker Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 121. Labcorp Main Business
Table 122. Labcorp Latest Developments
Table 123. NeoGenomics Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors
Table 124. NeoGenomics Tumor Biomarker Testing Product Offered
Table 125. NeoGenomics Tumor Biomarker Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 126. NeoGenomics Main Business
Table 127. NeoGenomics Latest Developments
Table 128. Exact Sciences Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors
Table 129. Exact Sciences Tumor Biomarker Testing Product Offered
Table 130. Exact Sciences Tumor Biomarker Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 131. Exact Sciences Main Business
Table 132. Exact Sciences Latest Developments
Table 133. Myriad Genetics Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors
Table 134. Myriad Genetics Tumor Biomarker Testing Product Offered
Table 135. Myriad Genetics Tumor Biomarker Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 136. Myriad Genetics Main Business
Table 137. Myriad Genetics Latest Developments
Table 138. Guardant Health Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors
Table 139. Guardant Health Tumor Biomarker Testing Product Offered
Table 140. Guardant Health Tumor Biomarker Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 141. Guardant Health Main Business
Table 142. Guardant Health Latest Developments
Table 143. Caris Life Sciences Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors
Table 144. Caris Life Sciences Tumor Biomarker Testing Product Offered
Table 145. Caris Life Sciences Tumor Biomarker Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 146. Caris Life Sciences Main Business
Table 147. Caris Life Sciences Latest Developments
Table 148. Tempus AI Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors
Table 149. Tempus AI Tumor Biomarker Testing Product Offered
Table 150. Tempus AI Tumor Biomarker Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 151. Tempus AI Main Business
Table 152. Tempus AI Latest Developments
Table 153. Natera Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors
Table 154. Natera Tumor Biomarker Testing Product Offered
Table 155. Natera Tumor Biomarker Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 156. Natera Main Business
Table 157. Natera Latest Developments
Table 158. Personalis Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors
Table 159. Personalis Tumor Biomarker Testing Product Offered
Table 160. Personalis Tumor Biomarker Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 161. Personalis Main Business
Table 162. Personalis Latest Developments
Table 163. Invivoscribe Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors
Table 164. Invivoscribe Tumor Biomarker Testing Product Offered
Table 165. Invivoscribe Tumor Biomarker Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 166. Invivoscribe Main Business
Table 167. Invivoscribe Latest Developments
Table 168. Biocartis Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors
Table 169. Biocartis Tumor Biomarker Testing Product Offered
Table 170. Biocartis Tumor Biomarker Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 171. Biocartis Main Business
Table 172. Biocartis Latest Developments
Table 173. Sysmex Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors
Table 174. Sysmex Tumor Biomarker Testing Product Offered
Table 175. Sysmex Tumor Biomarker Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 176. Sysmex Main Business
Table 177. Sysmex Latest Developments
Table 178. Leica Biosystems Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors
Table 179. Leica Biosystems Tumor Biomarker Testing Product Offered
Table 180. Leica Biosystems Tumor Biomarker Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 181. Leica Biosystems Main Business
Table 182. Leica Biosystems Latest Developments
Table 183. Cepheid Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors
Table 184. Cepheid Tumor Biomarker Testing Product Offered
Table 185. Cepheid Tumor Biomarker Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 186. Cepheid Main Business
Table 187. Cepheid Latest Developments
Table 188. Menarini Silicon Biosystems Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors
Table 189. Menarini Silicon Biosystems Tumor Biomarker Testing Product Offered
Table 190. Menarini Silicon Biosystems Tumor Biomarker Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 191. Menarini Silicon Biosystems Main Business
Table 192. Menarini Silicon Biosystems Latest Developments
Table 193. Veracyte Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors
Table 194. Veracyte Tumor Biomarker Testing Product Offered
Table 195. Veracyte Tumor Biomarker Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 196. Veracyte Main Business
Table 197. Veracyte Latest Developments
Table 198. Castle Biosciences Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors
Table 199. Castle Biosciences Tumor Biomarker Testing Product Offered
Table 200. Castle Biosciences Tumor Biomarker Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 201. Castle Biosciences Main Business
Table 202. Castle Biosciences Latest Developments
Table 203. OncoDNA Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors
Table 204. OncoDNA Tumor Biomarker Testing Product Offered
Table 205. OncoDNA Tumor Biomarker Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 206. OncoDNA Main Business
Table 207. OncoDNA Latest Developments
Table 208. ACT Genomics Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors
Table 209. ACT Genomics Tumor Biomarker Testing Product Offered
Table 210. ACT Genomics Tumor Biomarker Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 211. ACT Genomics Main Business
Table 212. ACT Genomics Latest Developments
Table 213. GC Genome Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors
Table 214. GC Genome Tumor Biomarker Testing Product Offered
Table 215. GC Genome Tumor Biomarker Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 216. GC Genome Main Business
Table 217. GC Genome Latest Developments
Table 218. Burning Rock Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors
Table 219. Burning Rock Tumor Biomarker Testing Product Offered
Table 220. Burning Rock Tumor Biomarker Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 221. Burning Rock Main Business
Table 222. Burning Rock Latest Developments
Table 223. Amoy Diagnostics Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors
Table 224. Amoy Diagnostics Tumor Biomarker Testing Product Offered
Table 225. Amoy Diagnostics Tumor Biomarker Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 226. Amoy Diagnostics Main Business
Table 227. Amoy Diagnostics Latest Developments
Table 228. Genetron Health Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors
Table 229. Genetron Health Tumor Biomarker Testing Product Offered
Table 230. Genetron Health Tumor Biomarker Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 231. Genetron Health Main Business
Table 232. Genetron Health Latest Developments
Table 233. 3DMed Diagnostics Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors
Table 234. 3DMed Diagnostics Tumor Biomarker Testing Product Offered
Table 235. 3DMed Diagnostics Tumor Biomarker Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 236. 3DMed Diagnostics Main Business
Table 237. 3DMed Diagnostics Latest Developments
Table 238. Singlera Genomics Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors
Table 239. Singlera Genomics Tumor Biomarker Testing Product Offered
Table 240. Singlera Genomics Tumor Biomarker Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 241. Singlera Genomics Main Business
Table 242. Singlera Genomics Latest Developments
Table 243. BGI Genomics Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors
Table 244. BGI Genomics Tumor Biomarker Testing Product Offered
Table 245. BGI Genomics Tumor Biomarker Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 246. BGI Genomics Main Business
Table 247. BGI Genomics Latest Developments
Table 248. Geneseeq Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors
Table 249. Geneseeq Tumor Biomarker Testing Product Offered
Table 250. Geneseeq Tumor Biomarker Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 251. Geneseeq Main Business
Table 252. Geneseeq Latest Developments
Table 253. Genecast Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors
Table 254. Genecast Tumor Biomarker Testing Product Offered
Table 255. Genecast Tumor Biomarker Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 256. Genecast Main Business
Table 257. Genecast Latest Developments


List of Figures
Figure 1. Tumor Biomarker Testing Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Tumor Biomarker Testing Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Tumor Biomarker Testing Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Tumor Biomarker Testing Sales Market Share by Country/Region (2025)
Figure 8. Tumor Biomarker Testing Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Tumor Biomarker Testing Market Size Market Share by Type in 2025
Figure 10. Global Tumor Biomarker Testing Market Size Market Share by Sample Source in 2025
Figure 11. Global Tumor Biomarker Testing Market Size Market Share by Delivery Model in 2025
Figure 12. Global Tumor Biomarker Testing Market Size Market Share by Detection Technology in 2025
Figure 13. Tumor Biomarker Testing in Lung Cancer
Figure 14. Global Tumor Biomarker Testing Market: Lung Cancer (2021-2026) & ($ millions)
Figure 15. Tumor Biomarker Testing in Breast Cancer
Figure 16. Global Tumor Biomarker Testing Market: Breast Cancer (2021-2026) & ($ millions)
Figure 17. Tumor Biomarker Testing in Colorectal
Figure 18. Global Tumor Biomarker Testing Market: Colorectal (2021-2026) & ($ millions)
Figure 19. Tumor Biomarker Testing in Prostate Cancer
Figure 20. Global Tumor Biomarker Testing Market: Prostate Cancer (2021-2026) & ($ millions)
Figure 21. Tumor Biomarker Testing in Blood Cancer
Figure 22. Global Tumor Biomarker Testing Market: Blood Cancer (2021-2026) & ($ millions)
Figure 23. Global Tumor Biomarker Testing Market Size Market Share by Application in 2025
Figure 24. Global Tumor Biomarker Testing Revenue Market Share by Player in 2025
Figure 25. Global Tumor Biomarker Testing Market Size Market Share by Region (2021-2026)
Figure 26. Americas Tumor Biomarker Testing Market Size 2021-2026 ($ millions)
Figure 27. APAC Tumor Biomarker Testing Market Size 2021-2026 ($ millions)
Figure 28. Europe Tumor Biomarker Testing Market Size 2021-2026 ($ millions)
Figure 29. Middle East & Africa Tumor Biomarker Testing Market Size 2021-2026 ($ millions)
Figure 30. Americas Tumor Biomarker Testing Value Market Share by Country in 2025
Figure 31. United States Tumor Biomarker Testing Market Size Growth 2021-2026 ($ millions)
Figure 32. Canada Tumor Biomarker Testing Market Size Growth 2021-2026 ($ millions)
Figure 33. Mexico Tumor Biomarker Testing Market Size Growth 2021-2026 ($ millions)
Figure 34. Brazil Tumor Biomarker Testing Market Size Growth 2021-2026 ($ millions)
Figure 35. APAC Tumor Biomarker Testing Market Size Market Share by Region in 2025
Figure 36. APAC Tumor Biomarker Testing Market Size Market Share by Type (2021-2026)
Figure 37. APAC Tumor Biomarker Testing Market Size Market Share by Application (2021-2026)
Figure 38. China Tumor Biomarker Testing Market Size Growth 2021-2026 ($ millions)
Figure 39. Japan Tumor Biomarker Testing Market Size Growth 2021-2026 ($ millions)
Figure 40. South Korea Tumor Biomarker Testing Market Size Growth 2021-2026 ($ millions)
Figure 41. Southeast Asia Tumor Biomarker Testing Market Size Growth 2021-2026 ($ millions)
Figure 42. India Tumor Biomarker Testing Market Size Growth 2021-2026 ($ millions)
Figure 43. Australia Tumor Biomarker Testing Market Size Growth 2021-2026 ($ millions)
Figure 44. Europe Tumor Biomarker Testing Market Size Market Share by Country in 2025
Figure 45. Europe Tumor Biomarker Testing Market Size Market Share by Type (2021-2026)
Figure 46. Europe Tumor Biomarker Testing Market Size Market Share by Application (2021-2026)
Figure 47. Germany Tumor Biomarker Testing Market Size Growth 2021-2026 ($ millions)
Figure 48. France Tumor Biomarker Testing Market Size Growth 2021-2026 ($ millions)
Figure 49. UK Tumor Biomarker Testing Market Size Growth 2021-2026 ($ millions)
Figure 50. Italy Tumor Biomarker Testing Market Size Growth 2021-2026 ($ millions)
Figure 51. Russia Tumor Biomarker Testing Market Size Growth 2021-2026 ($ millions)
Figure 52. Middle East & Africa Tumor Biomarker Testing Market Size Market Share by Region (2021-2026)
Figure 53. Middle East & Africa Tumor Biomarker Testing Market Size Market Share by Type (2021-2026)
Figure 54. Middle East & Africa Tumor Biomarker Testing Market Size Market Share by Application (2021-2026)
Figure 55. Egypt Tumor Biomarker Testing Market Size Growth 2021-2026 ($ millions)
Figure 56. South Africa Tumor Biomarker Testing Market Size Growth 2021-2026 ($ millions)
Figure 57. Israel Tumor Biomarker Testing Market Size Growth 2021-2026 ($ millions)
Figure 58. Turkey Tumor Biomarker Testing Market Size Growth 2021-2026 ($ millions)
Figure 59. GCC Countries Tumor Biomarker Testing Market Size Growth 2021-2026 ($ millions)
Figure 60. Americas Tumor Biomarker Testing Market Size 2027-2032 ($ millions)
Figure 61. APAC Tumor Biomarker Testing Market Size 2027-2032 ($ millions)
Figure 62. Europe Tumor Biomarker Testing Market Size 2027-2032 ($ millions)
Figure 63. Middle East & Africa Tumor Biomarker Testing Market Size 2027-2032 ($ millions)
Figure 64. United States Tumor Biomarker Testing Market Size 2027-2032 ($ millions)
Figure 65. Canada Tumor Biomarker Testing Market Size 2027-2032 ($ millions)
Figure 66. Mexico Tumor Biomarker Testing Market Size 2027-2032 ($ millions)
Figure 67. Brazil Tumor Biomarker Testing Market Size 2027-2032 ($ millions)
Figure 68. China Tumor Biomarker Testing Market Size 2027-2032 ($ millions)
Figure 69. Japan Tumor Biomarker Testing Market Size 2027-2032 ($ millions)
Figure 70. Korea Tumor Biomarker Testing Market Size 2027-2032 ($ millions)
Figure 71. Southeast Asia Tumor Biomarker Testing Market Size 2027-2032 ($ millions)
Figure 72. India Tumor Biomarker Testing Market Size 2027-2032 ($ millions)
Figure 73. Australia Tumor Biomarker Testing Market Size 2027-2032 ($ millions)
Figure 74. Germany Tumor Biomarker Testing Market Size 2027-2032 ($ millions)
Figure 75. France Tumor Biomarker Testing Market Size 2027-2032 ($ millions)
Figure 76. UK Tumor Biomarker Testing Market Size 2027-2032 ($ millions)
Figure 77. Italy Tumor Biomarker Testing Market Size 2027-2032 ($ millions)
Figure 78. Russia Tumor Biomarker Testing Market Size 2027-2032 ($ millions)
Figure 79. Egypt Tumor Biomarker Testing Market Size 2027-2032 ($ millions)
Figure 80. South Africa Tumor Biomarker Testing Market Size 2027-2032 ($ millions)
Figure 81. Israel Tumor Biomarker Testing Market Size 2027-2032 ($ millions)
Figure 82. Turkey Tumor Biomarker Testing Market Size 2027-2032 ($ millions)
Figure 83. Global Tumor Biomarker Testing Market Size Market Share Forecast by Type (2027-2032)
Figure 84. Global Tumor Biomarker Testing Market Size Market Share Forecast by Application (2027-2032)
Figure 85. GCC Countries Tumor Biomarker Testing Market Size 2027-2032 ($ millions)